News
![Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
![Form 8.3 - The Vanguard Group, Inc.: HomeServe plc](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Form 8.3 - The Vanguard Group, Inc.: HomeServe plc
![Form 8.3 - The Vanguard Group, Inc.: Euromoney Institutional Investor plc](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Form 8.3 - The Vanguard Group, Inc.: Euromoney Institutional Investor plc
![Form 8.3 - The Vanguard Group, Inc.: Countryside Partnerships plc](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Form 8.3 - The Vanguard Group, Inc.: Countryside Partnerships plc
![Form 8.3 - The Vanguard Group, Inc.: ContourGlobal plc](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Form 8.3 - The Vanguard Group, Inc.: ContourGlobal plc
![Form 8.3 - The Vanguard Group, Inc.: Capricorn Energy plc](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Form 8.3 - The Vanguard Group, Inc.: Capricorn Energy plc
![Form 8.3 - The Vanguard Group, Inc.: Capital & Counties Properties plc](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Form 8.3 - The Vanguard Group, Inc.: Capital & Counties Properties plc
![Form 8.3 - The Vanguard Group, Inc.: Brewin Dolphin Holdings plc](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Form 8.3 - The Vanguard Group, Inc.: Brewin Dolphin Holdings plc
![Form 8.3 - The Vanguard Group, Inc.: Biffa plc](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Form 8.3 - The Vanguard Group, Inc.: Biffa plc
![Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc
![Form 8.3 - The Vanguard Group, Inc.: Avast plc](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Form 8.3 - The Vanguard Group, Inc.: Avast plc
![Rights and Issues Investment Trust PLC: TEN-Tender Offer Clarification](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Rights and Issues Investment Trust PLC: TEN-Tender Offer Clarification
![DGAP-News: niiio subsidiary PATRONAS Collaborates with Temenos Multifonds to Deliver Holistic ‘Best-of-Breed’ Solution for Fund Administration](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
DGAP-News: niiio subsidiary PATRONAS Collaborates with Temenos Multifonds to Deliver Holistic ‘Best-of-Breed’ Solution for Fund Administration
![Aroundtown SA: Release of a capital market information](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Aroundtown SA: Release of a capital market information
![Form 8.3 - Maitland Institutional Services Limited: Re Euromoney Institutional Investor plc](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Form 8.3 - Maitland Institutional Services Limited: Re Euromoney Institutional Investor plc
![SThree: Change of Date of Q3 Trading Update](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
SThree: Change of Date of Q3 Trading Update
![Rights and Issues Investment Trust PLC: Net Asset Value(s)](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Rights and Issues Investment Trust PLC: Net Asset Value(s)
![Water Leaders to Accelerate Action Towards UN Sustainable Development Goals at IWA World Water Congress 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24843/Xylem_Logo.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBajhEIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--ff9cb640e3d6efcad8a7576b19f3edd05b9706a2/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Xylem_Logo.png?locale=us)
Water Leaders to Accelerate Action Towards UN Sustainable Development Goals at IWA World Water Congress 2022
There are 2.3 billion people who now live in water-stressed countries and 18 million people risk being displaced by floods every year1. Against this backdrop, global water technology company Xylem
![Hardman & Co Q&A on Surface Transforms (SCE): It's all in the detail](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Hardman & Co Q&A on Surface Transforms (SCE): It's all in the detail
![Chelverton UK Dividend Trust plc: Net Asset Value(s)](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Chelverton UK Dividend Trust plc: Net Asset Value(s)
![EQS-News: Yandex announces completion of News and Zen divestment and acquisition of Delivery Club](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
EQS-News: Yandex announces completion of News and Zen divestment and acquisition of Delivery Club
![Baloise to host ‘burnout prevention’ online event for entrepreneurs](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Baloise to host ‘burnout prevention’ online event for entrepreneurs
![Sensorion Receives Positive Opinion for Orphan Drug Designation for OTOF-GT for the Treatment of Otoferlin Gene-Mediated Hearing Loss From the European Medicine Agency: https://mms.businesswire.com/media/20210609005851/en/705797/5/logo-sensorion2.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK0dxVmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--df3db62501cd2dac51e6a4832a420790d1de65b6/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/logo-sensorion2.jpg?locale=us)
Sensorion Receives Positive Opinion for Orphan Drug Designation for OTOF-GT for the Treatment of Otoferlin Gene-Mediated Hearing Loss From the European Medicine Agency
Regulatory News:
Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
![Nanobiotix Announces Agreement in Principle to Restructure Existing Loan Agreement With European Investment Bank, Extending Operating Runway Into Q1 2024: https://mms.businesswire.com/media/20191111005579/en/744572/5/LOGO_NANO_EXPANDING_LIFE.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM25oRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--fb25377a8ea9e69d3b62f03b482ed70fb95efba1/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/LOGO_NANO_EXPANDING_LIFE.jpg?locale=us)
Nanobiotix Announces Agreement in Principle to Restructure Existing Loan Agreement With European Investment Bank, Extending Operating Runway Into Q1 2024
Regulatory News:
NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities
![Transgene Confirms the Potential of the Intravenous Route of its Invir.IO™ Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022 : https://mms.businesswire.com/media/20191209005543/en/255636/5/logo_TRANSGENE.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOFo2Rmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--73fe07bc16ac0607e1cc0e1a0b34e650fa94b07d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/logo_TRANSGENE.jpg?locale=us)
Transgene Confirms the Potential of the Intravenous Route of its Invir.IO™ Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces positive confirmatory data